News

Elucid Bioimaging receives Phase IIB Bridge Award

May 15, 2019
Elucid Bioimaging, Inc. today announced that that it has been awarded a highly-competitive Phase IIB Bridge Award from the National Heart, Lung, and Blood Institute of the NIH for its atherosclerosis evaluation software vascuCAP®. The competitive review criteria for considering grant applications under this program include scientific merit, clinical utility, and strength of the commercialization… View Article

vascuCAP Now Cleared for all Arteries

January 25, 2019
vascuCAP® software is now cleared for clinical use in all arterial beds for US and European markets see https://www.accessdata.fda.gov/cdrh_docs/pdf18/K183012.pdf. Extended labeling that describes the analytic performance was also cleared. Measurement performance not only for structural measurements of the vessel wall, lumen, stenosis and wall thickness but also tissue types comprising plaque composition measurements of lipid rich… View Article

Press Release: Elucid Bioimaging Announces New vascuCAP® Workflow and Features

January 2, 2018
Elucid Bioimaging is pleased to announce the latest release of its class-leading vascuCAP® software is now available to US and European clinical users and researchers world-wide. All users will have faster execution speed, improved visualization, streamlined workflow, and new reporting functions. Elucid’s CAPgraph® software is now also available to enable multi-user implementation and advanced reporting… View Article

Press Release: Elucid Bioimaging Announces Initial Q-CAMP CT Study Results Exceed Expectations

September 18, 2017
Wenham, Massachusetts – Elucid Bioimaging is pleased to announce that the lipid necrotic core, calcification, and plaque matrix objectives of its Q-CAMP study (NCT02143102) have been met. Elucid’s vascuCAP® software analysis of carotid CT Angiography (CTA) exceeded company expectations with its high correlation and low bias in its measurements of lipid rich necrotic core (LRNC),… View Article

Oral Presentation by Dr. Ajay Gupta, Weill Cornell Medical College, “SEMI-AUTOMATED DETECTION OF HIGH-RISK ATHEROSCLEROTIC CAROTID ARTERY PLAQUE FEATURES FROM COMPUTED TOMOGRAPHY ANGIOGRAPHY”, May 25 2017 – 26th European Stroke Conference, Berlin, Germany

May 25, 2017

Elucid Bioimaging Inc, announced today that it has received FDA 510(k) clearance to market its vascuCAP software (K163071) for evaluating CT images of patients with atherosclerosis.

May 25, 2017
May 25th, 2017 Wenham Massachusetts – Elucid Bioimaging Inc, announced today that it has received FDA 510(k) clearance to market its vascuCAP software (K163071) for evaluating CT images of patients with atherosclerosis. “This is a major milestone in the Elucid’s commercialization program”, remarked John Garber, Chief Executive Officer, “our visualization and measurement tools will be… View Article

Elucid Bioimaging is pleased to announce that they have met their recruiting targets for the Q-CAMP study

February 22, 2017
Wenham, MA–(BUSINESS WIRE) Elucid Bioimaging is pleased to announce that they have met their recruiting targets for the Q-CAMP study, enrollment has been completed and preliminary results will be announced in early June. Elucid started the Non-invasive Computer-Aided Phenotyping of Vasculopathy (Q-CAMP) study in 2014. Q-CAMP is a cross-sectional study of patients undergoing endarterectomy of… View Article